Pharmacy, Natural & Health Sciences

Pharmacy - Faculty Profiles

David F. Kisor

David F. Kisor, Pharm.D., FCP

Professor of Pharmaceutical Sciences, Director of Pharmacogenomics Education
260-470-2747
dfkisor@manchester.edu

Dr. Kisor is Professor and Director of Pharmacogenomics Education at Manchester University in Fort Wayne, Indiana. Previously, he was Chair of the Department of Pharmaceutical and Biomedical Sciences at the Raabe College of Pharmacy at Ohio Northern University. Kisor received his Bachelor of Science degree in Pharmacy from the University of Toledo and his PharmD from The Ohio State University. He completed a fellowship in Therapeutic Drug Monitoring and Pharmacokinetics at Ohio State. Beyond Kisor’s academic experience, he worked in the pharmaceutical industry at Burroughs Wellcome Co., now GlaxoSmithKline, where he was a research scientist in Pharmacokinetics and Drug Metabolism, working mostly on the development of purine analogs, including the drug nelarabine, a derivative of guanine, one of the “building blocks of life,” that was marketed in the United States in 2005. His focus at Manchester has been teaching pharmacogenomics and pharmacokinetics and relating genetics to pharmacokinetics. He has integrated pharmacogenomics into pharmacokinetic subject matter since 1998. He is a member of the American Pharmacists Association (APhA), the Personalized Medicine Coalition (PMC) and the American Association of Colleges of Pharmacy (AACP). He is a Fellow of the American College of Clinical Pharmacology. Kisor is a former national chair of the pharmacogenomics special interest group of AACP.

Areas of interest/Recent projects

  • Development of faculty
  • Pharmacogenetics/Pharmacogenomics Implementation
  • Pharmacogenetics/Pharmacogenomics of cathinones
  • Pharmacokinetics of cathinones
  • Teaching pharmacokinetics and pharmacogenetics

Publications/Presentations/Posters

Book:

  • Kisor DF, Kane, MD, Talbot JT, Bright DR, Sprague JE.  Pharmacogenes: Scientific Background and Clinical Applications.  Note: update of former title Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine. Manchester University 2017.
  • Kisor DF, Kane, MD, Talbot JT, Sprague JE.  Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine.  1st Ed. Jones and Bartlett Learning.  Burlington, MA. 2013.

Book Chapter:

  • Benedict N, Kisor DF.  The academic pharmacist in:  Remington:  The Science and Practice of Pharmacy.  22nd Ed. 2229-2234, 2013.

Papers:

  • Kisor DF, Calinski DM, Farrell CL. Beyond the didactic lecture: Pharmacogenomics in Pharmacy Education. Per Med. (in press) 2017.
  • Bright DR, Greco AJ, Langerveld A, Kisor DF. Clinical Implementation of Personalized Medicine in Community Pharmacies: Considerations for Clinicians. Per Med. (in press) 2017.
  • Grecco GG, Kisor DF, Magura JS, Sprague JE. Impact of common clandestine structural modifications on synthetic cathinone "bath salt" pharmacokinetics. Tox App Pharmacul (in press) 2017.
  • Bottorff MM, Bright DR, Kisor DF. Should pharmacogenomic evidence be considered in clinical decision making? Examples from cardiulogy. Pharmacotherapy (in press) 2017.
  • Beam TA, Loudermilk EF, Kisor DF. Pharmacogenetics and Pathophysiulogy of CACNA1S Mutations in Malignant Hyperthermia. Physiul Genomics. 49(2):81-87, 2017.
  • Roederer MW, Kuo GM, Kisor DF, Frye R, Hoffman JM, Jenkins J, Weitzel KW. Pharmacogenomics Competencies in Pharmacy Practice: A Blueprint for Change. J Am Pharm Assoc. 57(1):120-125, 2017.
  • Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. Educational strategies to provide pharmacogenomics-based care. Am J Health Syst Pharm. 73:1986-98, 2016.
  • Smith TR, Kearney E, Hulick PJ, Kisor DF. History repeats itself: The Family Medication History and Pharmacogenomics. Pharmacogenomics. 17(7):669-678, 2016.
  • Calinski DM, Kisor DF. An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype. Innov Pharm. 7(1):1-5, 2016.
  • Banks ML, Smith DA; Kisor DF; Poklis JL. Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys. Pharmacul Biochem Behav. 141:58-65, 2016.
  • Kisor DF, Smith HE, Grace E, Johnson SG, Weitzel KW, Farrell CL. The DNA of Pharmacy Education: CAPE Outcomes and Pharmacogenomics. AACP 2016. Found here Pgs. 1-38, 2016.
  • Kisor DF, Bright DR, Manion CR, Smith TR. Pharmacogenomics: Overview of Applications and Relation to Infusion Therapy. J Inf Nurs. 39(3):139-148, 2016.
  • Bright DR, Calinski DM, Kisor DF. Pharmacogenetic considerations in the elderly. Consult Pharm. 30(4), 228-239, 2015.
  • Kisor DF, Bright DR, Chen J, Smith TR. Academic and Professional Pharmacy Education: A Pharmacogenomics Certificate Training Program. Pers Med. 12(6):563-573, 2015.
  • Bright DR, Kisor DF, Smith A, Conaway M, Yu M. Implementation of a Pharmacogenetic Management Service for Post-Myocardial Infarction Care in a Community Pharmacy. Pers Med. 12(4), 319-325, 2015.
  • Westervelt P, Cho K, Bright DR, Kisor DF. Drug-Gene Interactions: Inherent Variability in Maintenance Dose Requirements. Pharm Ther. 39(9), 630-637, 2014.
  • Bova K, Bova S, Hill K, Dixon M, Ivankovic D, Kisor DF. Introducing Pharmacogenetics and Personalized Medicine via a Weblog. Innov Pharm. 5(2);1-11, 2014.
  • Kisor DF, Bright DR, Conaway MM, Bouts BA, Gerschutz G. Pharmacogenetics in the Community Pharmacy: Thienopyridine Selection Post Coronary Artery Stent Placement. J Pharm Prac. 27(4);416-419. 2014.
  • Kisor DF. Making personalized medicine an expectation of pharmacy students. Pers Med. 10(1):5-8, 2013. (invited editorial)
  • Kisor DF, Smith AJ. Therapeutic Actions and the Genetic Code: Examples of the application of pharmacogenetics. Ohio Pharmacist 62(12):7-12, 2013.
  • Kisor DF, Kroustos K. Pharmacogenomics in women’s health. U.S. Pharmacist. 38(9):70-80, 2013.
  • Kisor DF, Tice B. Implementing pharmacogenomics in pharmacy practice. Am Pharmacist. 47-61, 2013.
  • Kisor DF, Sprague JE.  The application of drug dosing guidelines based on preemptive genetic testing.  Spec Pharm Times. 4(3), 2013.
  • Shields KM, Sobota KF, Kroustos KR, Bright DR, North CL, Kisor DF. Implementation and evaluation of a student-led, online, longitudinal outpatient case elective. Curr Pharm Teach Learn. 5(5);351-357, 2013.
  • Kisor DF, Talbot JN, Stockert AL, Smith A. Exploring a laboratory model of pharmacogenetics as applied to clinical decision making. Innov Pharm. 4(2);1-12, 2013.
  • Kisor DF, Munro C, Loudermilk E.  Pharmacogenomics and the most commonly prescribed drugs of 2011.  Pharm Times. 78(12):85-96, 2012.
  • Rojeab Y, Martin S, White R, Montenery S, McWilliams M, Walker M, Kisor D.  In vitro dissulution and pilot pharmacokinetic studies of acetylsalicylic acid from an orally disintegrating tablet formulation of low-dose aspirin.  Int J Med Clin Res. 2:72-77, 2011.
  • Roecker AM, Stockert A, Kisor DF.  Nelarabine in the treatment of refractory T-cell malignancies.  Clin Med Insights Oncul. 4:133-151, 2010.
  • Likovich M, Derr A, Kane M, Kisor DF, Sprague JE.  Personalized medicine and the future of pharmacy practice.  Pharm Times. 76(4), 2010.